North America IgA Nephropathy Market – Industry Trends and Forecast to 2028

Market Analysis and Insights: North America IgA Nephropathy Market

North America IgA nephropathy market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses that the market is growing with a CAGR of 19.7% in the forecast period of 2021 to 2028 and is expected to reach USD 451.40 million by 2028 from USD 126.49 million in 2020. The increasing drug discoveries for IgA nephropathy are the major drivers that drive the market demand in the forecast period. The rise in IgA nephropathy disorder increases disease burden, increasing the demand for diagnosis and treatment products, thus driving the North America IgA nephropathy market growth.

IgA nephropathy, also known as Berger's disease, is a kidney disease caused by the build-up of IgA deposits in the kidneys, which cause inflammation and damage to the kidney tissues. Antibodies such as IgA are proteins produced by the immune system to shield the body from foreign substances, including bacteria and viruses. The complication of this disease is the ESKD which then needs dialysis for treatment.

The increasing IgA nephropathy targeted pipeline drugs allows the potential candidate to show the efficacy for IgA nephropathy treatment hence acts as a driver for the IgA nephropathy market. The cost of treatment of IgA nephropathy increases patients' pocket burden if reimbursement is absent, hence acting as a restraint for the IgA nephropathy market growth. Collaboration of market players for drug development increases the presence and innovation, hence acting as an opportunity for the IgA nephropathy market growth. Side effects associated with the treatment of IgA nephropathy and the COVID-19 impact on the immunosuppressive drugs market pose a challenge for the growth of the IgA nephropathy market.

The North America IgA nephropathy market report provides details of market share, new developments, and product pipeline analysis, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the IgA nephropathy market scenario, contact Data Bridge Market Research for an Analyst Brief; our team will help you create a revenue impact solution to achieve your desired goal.

North America IgA Nephropathy Market Scope and Market Size

North America IgA nephropathy market is segmented on the basis of the disease type, symptoms, type, population type, route of administration, end user, and distribution channel. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

• On the basis of disease type, the North America IgA nephropathy market is segmented into primary IgA nephropathy and secondary IgA nephropathy. In 2021, the primary IgA nephropathy segment is expected to dominate the market because the incidence of primary IgA nephropathy is more and can be diagnosed by blood or urine test easily.
• On the basis of symptoms, the North America IgA nephropathy market is segmented into haematuria, proteinuria, edema, and others. In 2021, the haematuria segment is expected to dominate the market as it is the most common and frequently used parameter for clinical examination and is detected by the amount of blood in the urine showing the occurrence of disease in the kidney.
• On the basis of type, the North America IgA nephropathy market is segmented into diagnosis and treatment. In 2021, the diagnosis segment is expected to dominate the market because prior given the treatment, the proper detection, and tracing of the IgA nephropathy is necessary. It is possible only through the primary detection such as blood and urine tests and confirmatory detection by kidney biopsy, which are the major factor of this segment.
• On the basis of population type, the North America IgA nephropathy market is segmented into paediatrics and adults. In 2021, the adults segment is expected to show significant growth because the studies showed the connection of this disease with aging.
• On the basis of route of administration, the North America IgA nephropathy market is segmented into oral, parenteral, and others. In 2021, the oral segment is expected to dominate the market due to the wide variety of oral product portfolios available in interstate commerce, which increases the market of this segment.
• On the basis of end user, the North America IgA nephropathy market is segmented into hospitals, clinics, home healthcare, and others. In 2021, the hospitals segment is expected to dominate the market due to its strong financial structure.
• On the basis of distribution channel, the North America IgA nephropathy market is segmented into direct tender, hospital pharmacy, retail pharmacy, online pharmacy, and others. In 2021, the direct tender segment accelerates revenue growth and provides tax benefits. The direct tender segment has been flourishing for the last few years, henceforth, affirmative illustrating the further growth of the market.

North America IgA Nephropathy Market Country Level Analysis

North America IgA nephropathy market is segmented on the basis of the disease type, symptoms, type, population type, route of administration, end user, and distribution channel.  

The countries covered in the North America IgA nephropathy market report are the U.S., Canada, and Mexico.

North America is expected to dominate the market due to the rise in demand for IgA nephropathy by researchers and scientists in the region. The U.S. is dominating the market and leading the growth in the North America market due to the increased presence of key market players in the region.

The country section of the report also provides individual market impacting factors and changes in market regulation that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, the presence and availability of North American brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of sales channels are considered while providing forecast analysis of the country data.

Increasing Acquisition and Merger is Creating New Opportunities for Players in the North America IgA Nephropathy Market

The North America IgA nephropathy market also provides you with a detailed market analysis for every country's growth. Additionally, it provides data regarding acquisition and agreement among the major market players and start-up companies. Moreover, the growing impact of research and development activities on the North America IgA nephropathy market growth pace. The data is available for the historical period 2010 to 2019.

Competitive Landscape and North America IgA Nephropathy Market Share Analysis

The North America IgA nephropathy market competitive landscape provides details by the competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width, and breadth, application dominance, and technology lifeline curve. The above data points provided are only related to the company’s focus related to the North America IgA nephropathy market.

The major players covered in the North America IgA nephropathy report are AstraZeneca, Novartis AG, Pfizer Inc., Zydus Cadila, Teva Pharmaceutical USA, Inc. (a subsidiary of Teva Pharmaceuticals Industries Ltd.), Hikma Pharmaceuticals PLC, LUPIN, Accord Health, Viatris Inc., Seimens Healthcare GmBH (a subsidiary of Seimens Healthineers AG), ARAKAY USA, Inc., Merck Sharp & Dohme. (a subsidiary of Merck & Co., Inc.), Strides Pharma Science Limited and Apotex Inc., among other domestic and global players. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Many contracts and agreements are also initiated by the companies worldwide, which accelerates the IgA nephropathy market.

For instance,

• In March 2017, Apotex Inc. Announced that they had invested USD 184 Million in Investment to Grow U.S. Manufacturing Presence. This is the Expansion Plan Comprises Company's Largest Investment in the United States. This has increased the company manufacturing to meet the demand for the product

Collaboration, joint ventures, and other strategies by the market players enhance the company's impression in the North America IgA nephropathy market, which also benefits the organization to improve their IgA nephropathy sales growth.

SKU-63014